Commentary

Podcast

Pharmacy Focus- Oncology Edition: Delayed Breast Cancer Screenings

Expert shares reasons why many women are behind on their annual breast cancer screenings, along with the latest cutting edge treatments in the breast cancer space.

About the Speaker

Bonni Lee Guerin, MD, is a hematologist/oncologist and director of the Breast Cancer Treatment and Prevention Program at Overlook Medical Center, Summit, NJ, Atlantic Health System.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com
Related Content
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
New Programs Aim to Improve Implementation of Cardiovascular Interventions
June 3rd 2025

New Programs Aim to Improve Implementation of Cardiovascular Interventions

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor